| OSRX® Brimonidine + Dorzolamide | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dosing | b.i.d. | ||||||||
| Chem Specs | brimonidine 0.15%, dorzolamide 2.0% | ||||||||
| Quantities | 5ml, | ||||||||
| Cost | 25.00 | ||||||||
| Class |
brimonidine: Relatively selective alpha-2 agonist. dorzolamide: Carbonic anhydrase inhibitor | ||||||||
| Usage | Single container preparation reduces cost and enhances compliance.
| Contraindications |
| brimonidine
Neonates and infants (under the age of 2 years). Brimonidine hypersensitivity. dorzolamide
Sulfonamide hypersensitivity. (Serious systemic reactions can occur.) Pediatric use |
Safety and effectiveness in pediatric patients have not been established.
| Pregnancy |
Dorzolamide: animal teratogenicity at 37 times the normal human ophthalmic dose. |
| Compounded in OSRX 503A/503B approved pharmacy. BAK preserved.
|
|
